Cologuard maker jumps as colon cancer screening now recommended earlier
Shares of Exact Sciences (EXAS) are on the rise after the American Cancer Society released an updated guideline for colorectal cancer screening, saying screening should begin at age 45 for people at average risk.
Previously, the guideline recommended screening begin at age 50 for people at average risk.
The American Cancer Society released an updated guideline for colorectal cancer screening.
Among the major guideline changes, the new recommendations say screening should begin at age 45 for people at average risk. Previously, the guideline recommended screening begin at age 50 for people at average risk.
Additionally, the American Cancer Society also recommended that people who are in good health and with a life expectancy of more than 10 years should continue regular colorectal cancer screening through the age of 75.
Recommendations for screening test options are also part of the guideline changes.
“There are some differences among the tests to consider, but the most important thing is to get screened, no matter which test you choose,” the American Cancer Society said in a statement, listing the differences between stool-based tests and visual exams.
After the American Cancer Society updated its guideline for colorectal cancer screening to recommend screening begin at age 45 for people at average risk, Leerink analyst Puneet Souda said this is “only directionally positive” for Exact Sciences.
#Souda said the ACS recommendation does not automatically translate into becoming a reality in clinical practice in the near-term, nor does it mean the USPSTF and NCCN automatically follow suit. Souda maintains an Outperform rating on Exact Sciences shares.
In Wednesday’s trading, shares of Exact Sciences have gained over 8% to $56.96. The company sells stool-based test Cologuard, a noninvasive colorectal cancer screening test.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.